Attendee search 

Founded in 2005, Baiyu is dedicated to R&D, manufacturing and marketing high-quality pharmaceutical products and APIs to all patients. As an innovation-based pharmaceutical company, we are specializing in chemical/botanical/biological medicinal products, especially ginkgo pharmaceutical products. And in 2020, aiming to protect everyone’s healthcare, Baiyu has built own subsidiary to produce high quality of Personal Protective Equipment to worldwide market.

With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.

Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.

东方富海成立于2006年，目前管理43只基金，管理总规模超200亿元人民币。

专注糖尿病和高尿酸血症

肿瘤和自身免疫疾病

上海复星医药是China医药领军企业，在生物制药领域地位突出。

医疗投资机构

An investment company founded by sinopharm

a stock company in China. Focus on the high quality finish product according to cGMP.

Shanghai复星医药（集团）股份有限公司（简称“复星医药”，股票代码：600196.SH，02196.HK）成立于1994 年，是China领先的医疗健康产业集团。复星医药的业务发展立足China、布局全球，以药品制造与研发为核心，覆盖医疗器械与医学诊断、医疗服务、医药分销与零售。

复星医药集团以创新研发为核心驱动因素，持续完善“仿创结合”的药品研发体系，打造了小分子创新药、高价值仿制药、生物药、细胞治疗等国际研发平台。

面向未来，复星医药集团在“4IN”（创新 Innovation、国际化 Internationalization、整合 Integration、智能化 Intelligentization）战略的指导下，秉承“持续创新·乐享健康”的品牌理念，致力于成为全球主流医疗健康市场的一流企业。

na